Yousuf Gaffar

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens

Rubén Niesvizky, Ian W. Flinn, Robert M. Rifkin et al. · Journal of Clinical Oncology · 2015 · 152 citations

Medicine, Pharmacology, Pharmacotherapy +14

Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients

Rubén Niesvizky, Ian W. Flinn, Robert M. Rifkin et al. · Blood · 2010 · 40 citations

Medicine, Hematology, Oncology +15

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Rubén Niesvizky, Ian W. Flinn, Robert M. Rifkin et al. · Blood · 2011 · 39 citations

Medicine, Hematology, Pharmacotherapy +13

Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Rubén Niesvizky, Ian W. Flinn, Robert M. Rifkin et al. · Blood · 2011 · 28 citations

Medicine, Hematology, Pharmacotherapy +16